DiaMedica Therapeutics Inc. DMAC R2KPHARMA
Company Overview
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +45.33% |
| 6 Months: | +37.76% |
| 3 Months: | +29.38% |
| 1 Month: | +11.37% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross9d ago
- RSI (14)63.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DMAC DiaMedica Therapeutics Inc. R2KPHARMA | 8.72 | -12.11 | $470.23M | 0.00% | -61.16% | -114.61% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 500.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.31M | -1.85M | -1.49M | -3.42M | -2.74M | -2.66M | -2.40M | -2.71M | -3.32M | -3.62M | -3.37M | -3.42M | -3.54M | -3.36M | -3.13M | -5.52M | -4.74M | -5.16M | -5.74M | -5.64M | -6.88M | -8.14M | -8.01M | -9.03M | -10.48M | -10.50M |
| Net Income | -650.00K | -1.74M | -1.39M | -3.25M | -2.47M | -2.45M | -2.42M | -2.47M | -3.19M | -3.62M | -3.27M | -3.45M | -3.51M | -3.36M | -3.06M | -5.27M | -4.48M | -4.47M | -5.15M | -5.12M | -6.27M | -7.71M | -7.70M | -8.62M | -10.04M | -10.14M |
| R&D Expense | 791.00K | 1.07M | 1.21M | 2.61M | 1.87M | 1.62M | 1.35M | 1.60M | 2.16M | 2.41M | 2.16M | 2.33M | 1.97M | 1.96M | 1.64M | 3.62M | 2.54M | 3.27M | 3.68M | 3.93M | 4.98M | 5.66M | 5.82M | 6.44M | 7.99M | 8.15M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 500.00K | - | - | - | - | - | - | - |
| Operating Income | -4.52M | -6.76M | -11.59M | -12.70M | -13.65M | -14.00M | -21.27M | -26.68M | -34.40M |
| Net Income | -4.26M | -5.73M | -10.65M | -12.29M | -13.59M | -13.68M | -19.38M | -24.44M | -32.77M |
| R&D Expense | 3.21M | 4.52M | 7.90M | 8.21M | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.80M | 18.34M | 9.05M | 28.09M | 45.55M | 34.40M | 54.16M | 46.34M | 61.37M |
| Total Equity | 1.11M | 799.00K | 17.02M | 7.62M | 26.01M | 44.02M | 31.83M | 51.06M | 40.72M | 56.11M |
| Cash & Equivalents | - | 1.35M | 16.82M | 3.88M | 7.41M | 4.71M | 4.73M | 4.54M | 3.02M | 15.65M |
| Current Liabilities | - | 1.00M | 1.30M | 1.32M | 2.03M | 1.52M | 2.17M | 2.79M | 5.39M | 5.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.90M | -5.70M | -9.10M | -9.19M | -12.25M | -11.51M | -18.73M | -22.08M | -29.06M |
| Investing Cash Flow | -22.00K | -50.00K | -3.91M | -16.13M | -20.54M | 11.54M | -18.30M | 8.56M | -2.19M |
| Financing Cash Flow | 3.54M | 21.22M | 70.00K | 28.84M | 30.09M | -6.00K | 36.84M | 11.99M | 43.88M |
| Capital Expenditure | -22.00K | -50.00K | -2.00K | -47.00K | -22.00K | -81.00K | -24.00K | -25.00K | -40.00K |
| Free Cash Flow | -3.92M | -5.75M | -9.10M | -9.23M | -12.27M | -11.59M | -18.75M | -22.10M | -29.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -1,352.2% | - | - | - | - | - | - | - |
| Net Margin % | - | -1,146.8% | - | - | - | - | - | - | - |
| ROE % | -533.2% | -33.7% | -139.8% | -47.3% | -30.9% | -43.0% | -38.0% | -60.0% | -58.4% |
| ROCE % | -565.6% | -39.7% | -149.9% | -48.7% | -31.0% | -43.4% | -41.4% | -65.1% | -61.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cooperman, Leon G. | 6.40% | 3.45M | $28.74M |
| 2 | Blackrock Inc. | 4.18% | 2.25M | $18.76M |
| 3 | Geode Capital Management, LLC | 1.66% | 894.12K | $7.45M |
| 4 | Paragon Associates & Paragon Associates Ii Joint Venture | 1.62% | 875.00K | $7.29M |
| 5 | Millennium Management Llc | 1.57% | 845.31K | $7.04M |
| 6 | State Street Corporation | 1.20% | 646.74K | $5.39M |
| 7 | Bleichroeder LP | 0.71% | 382.32K | $3.18M |
| 8 | Vanguard Capital Management LLC | 0.66% | 355.52K | $2.96M |
| 9 | Osaic Holdings Inc. | 0.63% | 338.11K | $2.82M |
| 10 | Northern Trust Corporation | 0.61% | 327.52K | $2.73M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMAC
DiaMedica Therapeutics Inc. (DMAC) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBLTWpkdTV4TGFVRlkzTzdoUGVtSUd2X21vYWNzRUppbVZwUmdkUnRGZG0za3cybWRFaHU3QjZuRjMyZUtpUndVREhiNmVSVnpqVnc?oc=5" target="_blank">DiaMedica Therapeutics Inc. (DMAC) Stock Price, News, Qu…
A stroke trial enrolled 200 people; an independent board will review data after their 90-day follow-ups. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPaV9xTkNpZ1RiTGM3cXVPazBIN3doeUFfX3RjZ2NjeGUyNmtPa0xoWk1VSVY1N1V6SFl5SmFRQTF5bE0zLXg2M0E3cERXQVlPUi1HOG4tX2FJOHdTRTVoWFNyNThURVY0UXR5NVNFcGxHNHZFb2ZLUXR3ZGNmRnVHYnp6NGxzdTNDMWNYT2…
Should I buy DiaMedica Therapeutics (DMAC) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5jU1FCRW5MRDFEZ2p6SXRZbDNGRW5LbDhnbHNyMG83ZE4xNExJaGl2MXZZdjdrRl9NLTQ2SWI1SkVWM000T3VIVUlaQ0VVSUVTSG1Fb3RkT3lheUNsU2dLTUNRcUY4SmFkSmFEZg?oc=5" target="_blank">Should I buy DiaMedic…
DMAC Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5jQUtlOUFlNko5SlM3NXdJMTBObE0tUnR0YzZQMHZrSVNpTnZxNXNWSGJRYUhZS1VBU0lFaXQ1a1NTUmhIRTJZcW5sNWVmN0hVTzFQSjBqQUpXLUJETWV1V0FrT0kzNEpnTDV4SExDOUNpYkJlcGFWZ3Vn?oc=5" target="_blank">DMA…
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPNlRjSTMxbm1CV2dPdVdIZVBuNFdHdE1qNmd3emVoSEtva052SHMyZ2JvWjNkOUxaOG1zYnNHLXhIUGpMMkppOEVmVlpNTHJMMlZ4VHIwbk5oSjVhaE54UFc4bUhSbzFjNS1ObGZkclZNcXNDU01UQzN0Qkc1aVBpSm5UZ1N2dGd0LUc5NW…
Why (DMAC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOZnZfSXlCQy1DWDRDN0JWbTR4aXByMVMzV0FiT3FZdGFtZmNvdGxFb0hvZDg2b1c0R1NsWnhZUmRJdTluOUpKUjE5Z281eTRfelB5U01aN3AxV2p0YTgtcDBEakNHeXBaWEFmSzVtM0oxNTgydENybFoyVUVaWGF3b3d6QnREZ3puWFZXME…
DMAC — Frequently Asked Questions
What is the current share price of DiaMedica Therapeutics Inc. (DMAC)?
As of 2026-10-23 16:27 PDT, DiaMedica Therapeutics Inc. (DMAC) trades at $8.72 on NasdaqCM. Its 52-week range is $5.30 to $9.39.
What is the market capitalisation of DMAC?
DiaMedica Therapeutics Inc. (DMAC) has a market capitalisation of $470.23M on NasdaqCM.
What is the P/E ratio of DMAC?
DMAC trades at a trailing price-to-earnings (P/E) ratio of -12.11. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 11.72.
What is the return on equity (ROE) of DMAC?
DMAC has a return on equity (ROE) of -114.61%. Its return on capital employed (ROCE) is -61.16%.
Is DMAC a good stock to buy?
This page provides a data-driven analysis of DiaMedica Therapeutics Inc. (DMAC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.